लोड हो रहा है...

Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept

Epidemiological studies indicate that diabetes is the second most common comorbidity in COVID-19 (coronavirus disease 2019). Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, exerts direct cardioprotective and nephroprotective effects. DARE-19 (Dapagliflozin in Respiratory Failure in Patie...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Cardiovasc Pharmacol
मुख्य लेखकों: Anastasiou, Georgia, Hatziagelaki, Erifili, Liberopoulos, Evangelos
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Journal of Cardiovascular Pharmacology 2021
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8253377/
https://ncbi.nlm.nih.gov/pubmed/34001719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FJC.0000000000001011
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!